Sophia Genetics Sa Stock Price, News & Analysis

SOPHiA GENETICS (Nasdaq: SOPH) has expanded its collaboration with AstraZeneca to enhance breast and prostate cancer detection through advanced AI technology. The partnership focuses on developing an optimized next-generation sequencing (NGS) solution that employs AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.

The companies have already developed a prototype demonstrating improved sensitivity in mutation detection. SOPHiA GENETICS will implement a Privileged Access Program for selected clinical laboratories, with broader commercial availability expected in 2026. The program includes a multi-center real-world evidence study to validate the technology's effectiveness in clinical settings.

SOPHiA GENETICS (Nasdaq: SOPH) has announced a strategic partnership with Jessa Ziekenhuis, one of Belgium's largest healthcare institutions, to enhance genomic testing and oncology research. The collaboration involves implementing SOPHiA DDM™ platform across Jessa's pathology operations, integrating six specialized applications for various cancer analyses.

The partnership aims to achieve significant operational improvements, including 30-50% reduction in hands-on time, up to 25% cost reduction, and faster testing turnaround times. Notably, the collaboration includes a unique arrangement where Jessa Ziekenhuis will share a NovaSeq sequencer with AZ Delta through the Bridge Consortium, optimizing sequencing capacity and knowledge sharing across Belgian healthcare institutions.

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2025 financial results with revenue of $18.3 million, up 16% year-over-year. The company achieved an adjusted gross margin of 74.4%, improving 120 basis points from the previous year. Despite growth, IFRS net loss increased 48% to $22.4 million.

Key operational highlights include performing 95,000 analyses on SOPHiA DDM™, signing 35 new core genomics customers, and securing a major AI breast cancer partnership with AstraZeneca. The company maintains its 2025 guidance of $72-76 million in revenue and expects to approach adjusted EBITDA breakeven by end of 2026.

SOPHiA GENETICS (Nasdaq: SOPH) has expanded its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) in a multi-year collaboration focused on breast cancer treatment optimization. The partnership will utilize SOPHiA GENETICS's multimodal AI Factories to analyze genomics, imaging, and clinical data to generate evidence on therapy efficacy and develop AI-powered predictive models.

The collaboration aims to generate real-world evidence in Europe and North America, leveraging one of healthcare's most diverse multimodal datasets to enhance clinical decision-making and treatment outcomes. The partnership highlights SOPHiA GENETICS's capabilities in managing complex healthcare data environments through secure, compliant, and scalable real-world AI applications.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before U.S. markets open.

The company will host a conference call to discuss the results and business outlook at 8:00 AM EDT / 2:00 PM CET. Investors can access the live webcast through the SOPHiA GENETICS Investor Relations Website, where a replay will also be available after the event.

SOPHiA GENETICS (SOPH) reported Q1 2025 financial results with revenue of $17.8 million, up 13% YoY (15% constant currency). The company achieved a record adjusted gross margin of 75.7%, improving from 70.5% last year. While IFRS net loss increased 27% to $17.4 million, adjusted EBITDA loss improved 24% to $9.8 million. Key operational highlights include: performing 93,000 analyses (+11% YoY), reaching 490 core genomics customers, and surpassing 2 million cumulative genomic profiles analyzed. The company maintained its 2025 guidance of revenue between $72-76 million and adjusted EBITDA loss of $35-39 million. Notable business momentum includes 30%+ U.S. revenue growth, expanded partnerships with major institutions like Mount Sinai and Mayo Clinic, and growing adoption of their MSK-ACCESS® powered platform. Management expects to approach adjusted EBITDA breakeven by end of 2026.

SOPHiA GENETICS and AstraZeneca are expanding their collaboration to accelerate global liquid biopsy testing deployment. The partnership will extend MSK-ACCESS powered with SOPHiA DDM to 30 clinical institutions worldwide in 2025.

Key highlights:

• The liquid biopsy test detects genomic alterations from a single blood draw using advanced algorithms to analyze circulating tumor DNA
• This testing method offers advantages when traditional tissue biopsies are impractical due to cost, time, or invasiveness
• New data presented at AACR shows consistent accuracy across different laboratory settings

The expanded rollout supports AstraZeneca's real-world evidence initiatives and aims to validate decentralized liquid biopsy testing's clinical impact. The collaboration addresses a major industry challenge, as site-to-site result consistency has historically limited liquid biopsy adoption. Recent study results confirm the test maintains high analytical performance across multiple centers, matching the original standards set at Memorial Sloan Kettering Cancer Center.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before U.S. markets open. The company will host a conference call to discuss the results and business outlook at 8:00 a.m. EDT / 2:00 p.m. CET on the same day. Investors can access the live webcast through the SOPHiA GENETICS Investor Relations Website, where a replay will also be available after the event.

SOPHiA GENETICS (SOPH) and Precision for Medicine have announced a strategic partnership to enhance biomarker discovery and precision medicine services. The collaboration integrates the SOPHiA DDM™ Platform into Precision for Medicine's offerings, providing advanced AI-driven analytics for clinical trials.

The partnership will leverage AI algorithms to analyze multimodal data, including genomic, radiomic, and clinical information, enabling better patient population targeting for clinical trials. A key feature includes the integration of MSK-ACCESS® powered with SOPHiA DDM™, a liquid biopsy test supported by AstraZeneca, which will facilitate retrospective clinical trial data analysis and improve patient stratification.

The collaboration combines Precision for Medicine's wet lab services and clinical trial expertise with SOPHiA GENETICS' AI-based genomic analysis tools, creating a comprehensive solution for biopharma companies to accelerate drug development, particularly in oncology, rare diseases, and genetic disorders.